Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia-A Podcast.

Journal

Targeted oncology

ISSN: 1776-260X

Titre abrégé: Target Oncol

Pays: France

ID NLM: 101270595

Informations de publication

Date de publication:
08 Mar 2024

Historique:

accepted: 01 12 2023

medline: 8 3 2024

pubmed: 8 3 2024

entrez: 8 3 2024

Statut: aheadofprint

Résumé

Older patients with acute lymphoblastic leukemia (ALL) have historically had poor outcomes (5-year survival rate, 20%) with standard intensive and dose-adjusted chemotherapy regimens, due to a high incidence of adverse biologic features including high-risk cytogenetics, presence of TP53 mutations, and poor tolerance to intensive therapy. Thus, there is an unmet medical need in this patient population. Inotuzumab ozogamicin is a humanized antibody-drug conjugate that targets CD22-positive leukemic blasts. It is approved for the treatment of relapsed or refractory ALL and has been shown to be effective and tolerable in older patients. Several ongoing trials in older patients with newly diagnosed ALL have yielded encouraging data with inotuzumab ozogamicin in induction alone and in combination with low-intensity chemotherapy. In this podcast, the authors summarize and highlight some of the recent findings on the use of inotuzumab ozogamicin as induction therapy for older adults with newly diagnosed ALL.

Identifiants

DOI: 10.1007/s11523-023-01023-y PMID: 38457052

pubmed: 38457052

doi: 10.1007/s11523-023-01023-y

pii: 10.1007/s11523-023-01023-y

doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Aldoss I, Forman SJ, Pullarkat V. Acute lymphoblastic leukemia in the older adult. J Oncol Pract. 2019;15:67–75.

doi: 10.1200/JOP.18.00271 pubmed: 30763199

Luskin MR. Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy? Hematology Am Soc Hematol Educ Program. 2021;2021:7–14.

doi: 10.1182/hematology.2021000226 pubmed: 34889389 pmcid: 8791151

Schwartz M, Wieduwilt MJ. New approaches to the treatment of older adults with acute lymphoblastic leukemia. Semin Hematol. 2020;57:122–9.

doi: 10.1053/j.seminhematol.2020.09.001 pubmed: 33256901

Wenge DV, Wethmar K, Klar CA, Kolve H, Sauer T, Angenendt L, et al. Characteristics and outcome of elderly patients (>55 years) with acute lymphoblastic leukemia. Cancers (Basel). 2022;14:565.

doi: 10.3390/cancers14030565 pubmed: 35158832

Boissel N, Huguet F, Leguary T, Mathilde H-B, Graux C, Chalandon Y, et al. In adults with Ph-negative acute lymphoblastic leukemia (ALL), age-adapted chemotherapy intensity and MRD-driven transplant indication significantly reduces treatment-related mortality (TRM) and improves overall survival—results from the Graall-2014 trial. Blood. 2022;140:112–4.

doi: 10.1182/blood-2022-157903

European Medicines Agency. Blincyto (blinatumomab). https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto . Accessed 25 Oct 2023.

U.S. Food and Drug Administration. BLINCYTO (blinatumomab). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm . Accessed 25 Oct 2023.

Kantarjian H, Jabbour E. Incorporating immunotherapy into the treatment strategies of B-cell adult acute lymphoblastic leukemia: the role of blinatumomab and inotuzumab ozogamicin. Am Soc Clin Oncol Educ Book. 2018;38:574–8.

doi: 10.1200/EDBK_199505 pubmed: 30231308

European Medicines Agency. Besponsa (inotuzumab ozogamicin). https://ema.europa.eu/en/medicines/human/EPAR/besponsa . Accessed 25 Oct 2023.

U.S. Food and Drug Administration. BESPONSA (inotuzumab ozogamicin). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm . Accessed 25 Oct 2023.

Chevallier P, Leguary T, Kim R, Delord M, Doubek M, Huguet F, et al. Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL): results of the EWALL-INO study. Blood. 2022;140:6114–6.

doi: 10.1182/blood-2022-166035

Nasnas P, Jabbour E, Short N, Ravandi F, Huang X, Jain N, et al. A phase II study of mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: updated results and predictors for outcomes. Blood. 2022;140:11679–82.

doi: 10.1182/blood-2022-168052

O'Dwyer KM. A chemotherapy-free regimen for older adults and relapsed or refractory B-ALL. Hematologist 2022;19. https://doi.org/10.1182/hem.V19.3.2022316

Stelljes M, Alakel N, Wasch R, Scholl S, Nachtkamp K, Rank A, et al. Inotuzumab ozogamicin induction followed by standard chemotherapy yields high remission rates and promising survivalin older (>55 years) patients with de novo B-lymphoblastic leukemia (GMALL-Initial1 trial). Blood. 2022;140:510–2.

doi: 10.1182/blood-2022-162235

Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10:e433–44.

doi: 10.1016/S2352-3026(23)00073-X pubmed: 37187201